Atomwise pursues 15 collaborations for COVID-19 treatments

By The Science Advisory Board staff writers

May 22, 2020 -- Small molecule drug discovery company Atomwise has announced it is collaborating with 15 institutions to develop broad-spectrum therapies for coronaviruses, including the novel coronavirus responsible for COVID-19.

Participating institutions include the following:

  • University of Mannitoba
  • Columbia University
  • University of Connecticut
  • University of Kentucky
  • University of South Australia
  • University of Texas Medical Branch Health
  • Jazan University
  • Dana-Farber Cancer Institute
  • University of Texas Health Science Center at San Antonio
  • University of Toledo
AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...
New platform includes biological similarities to accelerate drug discovery
A new open-access tool provides information on the effects of nearly 1 million compounds in a wide range of biological settings. The new tool, published...
Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.
Human enzymes are implicated in SARS-CoV-2 evolution and spread
Two human deaminase enzymes that edit viral RNA inside cells could have implications for the evolution of SARS-CoV-2 and the spread of the infection,...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter